Intensive glucose-lowering treatment among patients with non-insulin-requiring type 2 diabetes may increase the risk of hypoglycemia.
C linical guidelines recommend targeting a hemoglobin A 1c (HbA 1c ) level less than 7.0% for most nonpregnant adults with type 2 diabetes. Although tight glycemic control may have benefits for some patients with type 2 diabetes, achieving an HbA 1c level of less than 7.0% in others may result in higher burden of treatment, higher cost, more adverse drug reactions, and increased risk of hypoglycemia. [1] [2] [3] [4] In particular, patients with complex health problems, limited life expectancy, and advanced age are unlikely to benefit from tight glycemic control and are more likely to be harmed by it compared with younger, healthier patients. [5] [6] [7] [8] [9] [10] [11] [12] Accordingly, the American Geriatrics Society (AGS) Choosing Wisely initiative advises against use of medications other than metformin to achieve an HbA 1c level of less than 7.5% in most older adults with diabetes because of the risk of hypoglycemia and other harms, including mortality. 13 Instead, the AGS recommends targeting an HbA 1c level of 7.0% to 7.5% in healthy older adults with a long life expectancy, 7.5% to 8.0% in adults with moderate comorbidity and a life expectancy of less than 10 years, and 8.0% to 9.0% in patients with multiple comorbidities and a shorter life expectancy. 13 These recommendations are consistent with, although not explicitly stated by, other clinical guidelines that promote individualized evidence-based diabetes care. [14] [15] [16] [17] [18] [19] [20] [21] However, despite these recommendations, intensive control remains prevalent among older, sicker patients with diabetes.
22,23
Prior studies 22, 23 have not assessed the prevalence or effect of intensive treatment among younger patients or those using medications other than insulin or sulfonylureas. Moreover, relatively little is known about treatment practices and outcomes among patients once they achieve recommended tight glycemic targets. A recent study 24 from the US Veterans
Health Administration revealed that treatment is rarely deintensified among patients with very low (<6.0%) and moderately low (6.0%-6.4%) HbA 1c levels. In addition to the lack of deintensification, patients with controlled diabetes (HbA 1c level <7.0%) are also at risk for treatment intensification and potentially unnecessary polypharmacy. High rates of redundant HbA 1c testing were previously found among low-risk patients with stable, controlled, non-insulin-requiring type 2 diabetes. 25 Such overtesting was associated with treatment intensification, although overall treatment intensity could not be ascertained. Moreover, that study 25 focused specifically on low-risk patients rather than patients with clinical complexity. The goals of this study were therefore to quantify the prevalence of intensive treatment specifically among patients with clinically complex controlled type 2 diabetes and to estimate the association between intensive treatment, clinical complexity, and incidence of severe hypoglycemia.
Methods

Data Source
We conducted a retrospective analysis of data from the OptumLabs Data Warehouse (OLDW), a deidentified administrative claims database of more than 100 million individuals enrolled in private and Medicare Advantage plans across the United States (eMethods 1 in the Supplement). 26, 27 There was no patient involvement in this study. Study data were accessed using techniques adherent to the Health Insurance Portability and Accountability Act of 1996, and because this study involved analysis of preexisting, deidentified data, the Mayo Clinic Institutional Review Board deemed it exempt from institutional review board approval.
Study Population
We identified adults (≥18 years old) with stable, controlled type 2 diabetes from January 1, 2001, through December 31, 2011, who had 2 consecutive HbA 1c tests that revealed levels less than 7.0% within a 24-month period ( Figure 1 and eMethods 1 and eFigure 1 in the Supplement). Date of cohort entry was defined by the second (index) HbA 1c test. As shown in Figure 1 and We excluded 12 108 patients with severe hypoglycemia or hyperglycemia during the 12 months preceding the index HbA 1c because they are at increased risk for recurrent hypoglycemia and likely not subject to usual care; 52 016 patients with type 1, gestational, nonclinical, and secondary diabetes because these conditions may have different treatment goals and natural histories; 10 134 patients with any insulin prescription during 120 days preceding the index date because insulin is a known risk factor for hypoglycemia and claims data do not allow for ascertainment of insulin dose and treatment intensity change; 214 033 patients with lack of continuous enrollment for 24 months; 8999 patients younger than 18 years; and 1141 patients with incomplete demographic or enrollment information.
Patients entered the cohort once, the first time they became eligible, and were followed for 24 months (up to 2013). They were stratified on the basis of index HbA 1c measurements into 3 categories based on guideline recommendations for diabetes diagnosis and management: 5.6% or less, 5.7% to 6.4%, and 6.5% to 6.9%. [14] [15] [16] [17] [18] [19] [20] Patients were censored on a severe hyperglycemic event because that may precipitate changes in therapy and confound analyses.
Clinical Complexity
High vs low clinical complexity was defined based on the framework developed by the American Diabetes Association and the AGS 21 as a composite measure of age of 75 years or older or high comorbidity burden defined by the presence of endstage renal disease, dementia, or 3 or more serious chronic conditions (eMethods 3 in the Supplement). these patients' diabetes was already controlled per the guidelines). [14] [15] [16] [17] [18] [19] [20] For patients with an index HbA 1c level of 6.5% to 6.9%, intensive treatment was defined as the addition of 2 or more drugs or insulin after the index HbA 1c test date (no baseline treatment criterion). The last definition is a conservative criterion that underestimates intensive treatment as defined by most professional societies that recommend targeting an HbA 1c level of 7.0% rather than 6.5% and may view any treatment escalation at this point to be intensive treatment. [15] [16] [17] [18] [19] [20] None of the guidelines recommend the addition of 2 drugs for HbA 1c levels of 6.5% to 6.9%. [14] [15] [16] [17] [18] [19] [20] Treatment deintensification was defined by removing 1 or more drugs within 120 days after the index HbA 1c test date. Treatment regimens that did not meet the criteria for intensive treatment were classified as standard treatment.
Independent Variables
Severe Hypoglycemia 
Sensitivity Analyses
To separate the incidence of hypoglycemia caused by sulfonylurea agents vs otherwise intensive treatment, we conducted a sensitivity analysis for the risk of hypoglycemia (observed and risk adjusted) after excluding 7601 patients receiving sulfonylurea or glinide drugs after the index HbA 1c test date (eMethods 4 in the Supplement). Furthermore, because metformin may be used to treat prediabetes and other conditions, we conducted a second sensitivity analysis that excluded 5030 patients classified as receiving intensive treatment solely on the basis of metformin (eMethods 5 in the Supplement).
Statistical Analysis
Data are presented as frequencies and means for all variables. Univariate between-group comparisons were performed using χ 2 tests for categorical and binary variables and KruskalWallis tests for continuous variables. Multivariable logistic regression separately examined the risk-adjusted probabilities of intensive treatment and severe hypoglycemia. Adjustment variables were set to the sample means 30 of sex, race (white, nonwhite, unknown), household income, US region, index HbA 1c test date, and health care professional specialty. Risk-adjusted probabilities and 95% CIs for intensive treatment were calculated for patients with low and high clinical complexity, adjusting for the aforementioned variables. The association between intensive treatment and severe hypoglycemia was examined in a second logistic regression model in which the main predictor was a 4-level measure of patient complexity and treatment intensity: (1) low complexity with standard treatment, (2) low complexity with intensive treatment, (3) high complexity with standard treatment, and (4) high complexity with intensive treatment. Adjustment variables were set to the sample means of index HbA 1c level, medications used after testing, and the aforementioned variables. Analyses were conducted using SAS statistical software, version 9.3 (SAS Institute Inc), and STATA software, version 13.1 (StataCorp).
Results
Study Cohort
Baseline characteristics of the 31 542 patients included in the study stratified by clinical complexity are given in Table 1 
Prevalence of Intensive Treatment
In total, 8048 patients (25.5%) were treated intensively, including 7317 patients (26.5%) with low clinical complexity and 731 patients (18.7%) with high clinical complexity ( (Figure 2 ). In contrast, among patients with high clinical complexity, the risk-adjusted probability of severe hypoglycemia increased significantly with intensive treatment from 1.74% (95% CI, 1.28%-2.20%) with standard treatment to 3.04% (95% CI, 1.91%-4.18%) with intensive treatment (absolute difference, 1.30%; 95% CI, 0.10%-2.50%). The ORs of severe hypoglycemia were 1.72 (95% CI, 1.29-2.31) for high complexity with standard treatment vs low complexity with standard treatment groups, 3.05 (95% CI, 1.99-4.67) for high complexity with intensive treatment vs low complexity with standard treatment groups, and 1.77 (95% CI, 1.12-2.80) for high complexity with intensive treatment vs high complexity with standard treatment groups ( Figure 3 ). Sulfonylurea and glinide therapy significantly raised the risk of severe hypoglycemia (OR, 2.19; 95% CI, 1.77-2.71). Patients treated by endocrinologists had significantly higher risk of hypoglycemia (OR, 1.65; 95% CI, 1.25-2.20), even after adjustment for the HbA 1c level and medications used.
To determine whether our findings were driven by use of sulfonylureas, we performed sensitivity analyses excluding individuals using insulin secretagogues after the index HbA 1c test date. All results remained consistent, although not always statistically significant given the smaller sample size (eResults 1, eTable 2, and eTable 3 in the Supplement). None of the study results were altered by excluding patients who were classified as intensively treated on the basis of metformin use or start only (eResults 2, eTable 4, and eTable 5 in the Supplement).
Discussion
In this large national cohort of adults with controlled type 2 diabetes, more than a quarter of patients received intensive glucose-lowering therapy, including nearly 20% of patients with clinical complexity whose advanced age and comorbidities placed them at risk for treatment-related adverse events without substantial long-term benefit. 12 Indeed, we found that even with standard glucose-lowering treatment, patients with high clinical complexity had almost double the rate of severe hypoglycemia compared with patients with low clinical complexity, and their risk of severe hypoglycemia was further nearly doubled by intensive treatment. Intensive treatment did not, however, significantly increase hypoglycemia risk among patients with low clinical complexity. Recent guidelines, issued between 2010 and 2015, recommend initiation or escalation of pharmacotherapy for diabetes when the HbA 1c level exceeds recommended targets (6.5% or 7.0%) in patients with low risk for hypoglycemia, low comorbidity burden, and life expectancy consistent with anticipated benefits of glycemic control. [14] [15] [16] [17] [18] [19] [20] However, 1731 patients (5.5%) in our study, including 139 patients (3.6%) with high clinical complexity, began treatment or had their treatment intensified despite HbA 1c levels much lower than these thresholds. Treatment deintensification is also an important aspect of individualized diabetes management, and clinical inertia encompasses not only failure to intensify therapy in response to elevated HbA 1c levels 31 but also failure to deescalate therapy in response to low HbA 1c levels, particularly if treated with multiple glucose-lowering medications. In our study, 5053 patients (76.0%) receiving intensive treatment did not have their treatment deescalated, including 482 intensively treated patients (77.7%) with high clinical complexity. These data are similar to rates reported by Sussman and colleagues 24 in the US Veterans Health Administration. Such failure to deescalate therapy in patients with very low HbA 1c levels increases the risk of hypoglycemia, has no proven clinical benefit, exposes patients to potential adverse effects, and increases burden of treatment.
32
Our study identified several factors associated with intensive treatment and hypoglycemia. Women and nonwhite patients were less likely to be treated intensively, which may reflect underlying disparities in diabetes care. 33, 34 Patients treated by endocrinologists and nephrologists were more likely to be treated intensively, consistent with prior studies 35, 36 and possibly attributable to greater emphasis on lowering HbA 1c levels to reduce complications or a focus on treating diabetes without placing it in the context of multiple potentially competing diseases. Patients under endocrinology and nephrology care were also more likely to experience severe hypoglycemia even after treatment intensity and medical complexity were accounted for, warranting further investigation. Furthermore, we examined the often concurrent effects of sulfonylurea use and intensive treatment on hypoglycemia. We were concerned to find significantly more sulfonylurea and glinide use among patients with high clinical complexity (6294 low complexity patients [22.8%] and 1307 high complexity patients [33.4%] were treated with either sulfonylurea or glinide after the index HbA 1c test), despite the AGS strongly advising against sulfonylurea use by elderly individuals. 37 As expected, sulfonylureas increased hypoglycemia risk irrespective of treatment intensity. However, we also found that patients with high clinical complexity had significantly higher rates of severe hypoglycemia even without sulfonylurea use, and intensive treatment that does not include sulfonylureas may further elevate hypoglycemia risk. The rates of intensive treatment decreased during the study, particularly after 2009. This finding may be attributable to increasing uncertainty about long-term benefits of tight glycemic control 4, 38, 39 and awareness of hypoglycemia risk posed by targeting HbA 1c levels less than 6.5% to 7.0%. 2, 3 However, the association between intensive treatment and hypoglycemia remained unchanged over time, despite more prevalent use of novel glucose-lowering agents with lesser risk of hypoglycemia. 36, 40, 41 Intensive treatment with any glucoselowering drugs, even those not typically associated with hypoglycemia, should therefore be prescribed with caution, particularly to patients with high clinical complexity. Our study has several important limitations, including stringent inclusion criteria that restricted the population to Adjusted Probability of Severe Hypoglycemia (95% CI) There is an increasing consensus that overtreatment and overtesting expose some patients to services they may not need or prefer or that may harm them. This consensus first achieved national prominence with the Choosing Wisely campaign, and in fact, the American Geriatric Society has a Choosing Wisely recommendation on avoiding intensive medication treatment for diabetes in most older adults. 6 The preponderance of recommendations for decreasing overuse focus on avoiding one-time diagnostic procedures or treatment at the beginning of a discrete episode of care, such as not treating with antibiotics for acute sinusitis. However, a substantial amount of health care involves the long-term use of medical interventions for chronic and ongoing conditions, such as diabetes. Little guidance exists on when physicians and patients should begin the process for deintensifying medical servicesstopping or scaling back the intensity or frequency of medical interventions that are currently part of a patient's ongoing management.
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